A downgrade from Buy to Hold typically indicates a reduced expectation of performance and can lead to a negative investor sentiment. The substantial decrease in price target from $27 to $12 suggests a significant revision of the company's valuation, which could result in a short-term decline in Agilon Health's stock price.